UK | GW Pharma Denied Blanket Patent on Treating Epilepsy with Cannabinoids

screen shot 2019-01-13 at 09.26.55
The GW Pharmaceuticals cannabis facility in Sittingboune, England. PHOTO: Jason Alden

When UK-based GW Pharmaceuticals successfully convinced the FDA and the DEA to allow them to bring their cannabis-derived CBD isolate tincture to the U.S. market last year, surely some bottles got popped at the GW HQ as their anti-seizure medication, Epidiolex, stood unimpeded on a path to piles of cash.


Source: reposted by Cannabis News World . Original article by Beard Bros Crew

NuMeds superior strength logo banner hi res 300dpi

This site uses Akismet to reduce spam. Learn how your comment data is processed.